Barclays Upgrades Beta Bionics (NASDAQ:BBNX) to Strong-Buy

Beta Bionics (NASDAQ:BBNX) was upgraded by equities researchers at Barclays to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird upped their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. Wells Fargo & Company started coverage on Beta Bionics in a research note on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price on the stock. William Blair started coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating on the stock. UBS Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a report on Tuesday, September 15th. Finally, Wall Street Zen upgraded Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and an average target price of $23.50.

Beta Bionics Trading Down 3.6%

Shares of NASDAQ:BBNX opened at $17.43 on Tuesday. The company has a 50 day moving average of $18.66 and a 200 day moving average of $14.96. The stock has a market cap of $784.18 million, a P/E ratio of -10.56 and a beta of 3.39. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million for the quarter. On average, equities analysts forecast that Beta Bionics will post -2.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the transaction, the insider directly owned 87,157 shares in the company, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the transaction, the chief financial officer owned 159,378 shares in the company, valued at $3,045,713.58. This trade represents a 4.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 97,697 shares of company stock valued at $1,907,034 over the last quarter. Insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC lifted its holdings in shares of Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares during the last quarter. BlackRock Inc. bought a new position in shares of Beta Bionics during the 2nd quarter valued at $52,340,000. Bank of New York Mellon Corp bought a new position in shares of Beta Bionics during the 2nd quarter valued at $1,926,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics in the 4th quarter worth $40,437,000. Finally, Squarepoint Ops LLC purchased a new position in Beta Bionics in the 2nd quarter worth $2,524,000.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Barclays upgrade: Barclays raised Beta Bionics to “strong-buy,” potentially supporting investor confidence and demand for the shares. Barclays upgrades Beta Bionics
• Positive Sentiment: Mint clearance and valuation revisions: A report said the company’s fair-value estimate increased following Mint clearance and changes to analyst price targets, suggesting some analysts see improved commercial or regulatory prospects. Beta Bionics fair value rises after Mint clearance
• Neutral Sentiment: Legal deadline: Multiple law firms are soliciting investors who purchased BBNX shares between July 30, 2025, and February 24, 2026, ahead of a November 3, 2026 lead-plaintiff deadline. These notices largely repeat the same underlying lawsuit rather than represent separate new cases. Rosen Beta Bionics class action notice
• Negative Sentiment: Securities litigation and FDA concerns: Beta Bionics faces a securities class action alleging that management understated the significance of an FDA Form 483 and concerns involving its automated insulin-delivery system, iLet. Reports allege more than 18,000 unreported complaints and say subsequent FDA disclosures contributed to a sharp prior decline in the shares. The litigation creates reputational, regulatory and potential financial risks. Beta Bionics securities class action alert

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.